natgillin/translations-raw huggingface dataset:
Beholder til 300 mg hårde kapsler – pakning med 200
Bottle immediate packaging for 300 mg hard capsules – pack of 200
BEHOLDER TIL 60 OG 90 HÅRDE KAPSLER
BOTTLES FOR 60 AND 90 HARD CAPSULES
Beholder til 75 mg hårde kapsler – pakning med 200
Bottle immediate packaging for 75 mg hard capsules – pack of 200
BEHOLDER TIL PUSTEPROVEN: GLAS ELLER PLASTIK
BREATH SAMPLE CONTAINERS: GLASS OR PLASTIC
Beholder til skarpt affald
Sharps disposal container
BEHOLDER-ETIKET – 10.000 enheder
BOTTLE LABEL - 10,000 unit strength
BEHOLDER-ETIKET – 25.000 enheder
BOTTLE LABEL - 25,000 unit strength
BEHOLDER-ETIKET – 40.000 enheder
BOTTLE LABEL - 40,000 unit strength
BEHOLDER-ETIKET – 5.000 enheder
BOTTLE LABEL - 5,000 unit strength
Beholder:
Bottle
Beholder:
Bottle pack:
Beholder:
Containers:
Beholder: EU/1/06/343/001 30 filmovertrukne tabletter
Bottle pack: EU/1/06/343/001 30 film-coated tablets
Beholder: EU/1/06/343/002 30 filmovertrukne tabletter
Bottle pack: EU/1/06/343/002 30 film-coated tablets
Beholder: Hold beholderen tæt tillukket for at beskytte mod fugt.
Bottle: Keep the bottle tightly closed in order to protect from moisture
Beholdere
bottle
Beholdere (HDPE)
bottle (HDPE)
beholdere (HDÅE)
bottle (HDPE)
Beholdere indeholdende 30 eller 100 filmovertrukne tabletter.
Bottles containing 30 or 100 tablets.
Beholdere indeholder 30 eller 100 filmovertrukne tabletter.
Bottles contain 30 or 100 film-coated tablets.
Beholdere med flydende kvælstof og vaccine bør kun håndteres af særligt uddannet personale.
Liquid nitrogen containers and vaccine ampoules should be handled by properly trained personnel only.
Beholdere med fortyndet vaccine må ikke genbruges.
Do not re-use opened containers of diluted vaccine.
Beholdere:
Bottles:
Beholdere:
Containers:
Beholdere: egnede beholdere, såsom kromatografikar eller 1000 ml Erlenmeyer-kolbe.
Containers: appropriate containers such as chromatography tank or 1 000 mL Erlenmeyer flasks.
Beholdere: EU/1/06/343/001
Bottle packs: EU/1/06/343/001
Beholdere: EU/1/06/343/002
Bottle packs: EU/1/06/343/002
Beholdere: må ikke opbevares ved temperaturer over 25 °C. Beholderen skal holdes tæt tillukket.
Bottle packs: do not store above 25°C. Keep the bottle tightly closed.
Beholdere: Tabletterne udleveres i en plastbeholder med børnesikret låg.
Bottles: The tablets are supplied in a plastic bottle with a child-resistant plastic cap.
Beholderen bortskaffes efter lægens, sygeplejersken eller apotekets instrukser.
Dispose the puncture-proof container as instructed by your doctor, nurse or pharmacist.
Beholderen indeholder 180 depottabletter.
Bottles contain 180 prolonged-release tablets.
Beholderen indeholder et tørremiddel i en lille cylinderformet beholder.
The bottle contains a desiccant in a small cylinder shaped container.
Beholderen lukkes til og omrystes forsigtigt til alt pulveret er opløst.
Close the jar and shake it carefully until all the powder is dissolved.
Beholderen lukkes til og omrystes forsigtigt, til alt pulveret er helt opløst.
The jar is closed and carefully shaken until all the powder has dissolved completely.
Beholderen med brugte nåle og sprøjter bortskaffes i henhold til lokale myndighedskrav.
Dispose of your sharps container according to your local regulations
Beholderen må ikke opbevares uden for køleskab i mere end 30 dage.
The bottle should not be removed from refrigerated conditions for more than 30 days.
Beholderen og opløsningen skal inspiceres inden brug som beskrevet under pkt.
The container and the solution should be inspected prior to use as described in section 6.6.
Beholderen og opløsningen skal inspiceres inden brug.
The container and the solution should be inspected prior to use.
Beholderen opbevares utilgængeligt for born.
Keep this container out of the reach and sight of children
Beholderen opbevares utilgængeligt for børn
Keep this container out of the reach and sight of children
Beholderen opbevares utilgængeligt for børn
Keep this container out of the sight and reach of children
Beholderen opbevares utilgængeligt for børn.
Keep this container out of the reach and sight of children.
Beholderen opbevares utilgængeligt for børn.
Keep this container out of the sight and reach of children
Beholderen opbevares utilgængeligt for børn.
Keep this container out of the sight and reach of children.
Beholderen til denne vaccine indeholder latexgummi.
The container of this vaccine contains latex rubber.
Beholderen til dette lægemiddel indeholder latexgummi.
The container of this medicinal product contains latex rubber.
Beholderen åbnes ved at trykke det børnesikrede låg ned, mens der drejes mod uret.
Open bottles by pressing the child proof cap down and turning it counter-clock wise.
Beholderen, som er mærket med "13C-urinstof pulver" tages ud af pakningen, åbnes og fyldes trekvart op med postevand.
The jar labelled “13C-urea powder” is taken from the test set, opened, and filled up to three quarters of its volume with tap water.
Beholderen, som er mærket med ”13C-urinstof pulver” tages ud af testpakningen, åbnes og fyldes trekvart op med postevand.
The jar labelled “13C-urea powder” is removed from the pack, opened, and filled up to about three quarters with tap water.
Beholderen, som er mærket med ”13C-urinstof pulver” tages ud af testpakningen, åbnes og fyldes trekvart op med postevand.
The jar labelled “13C-urea powder” is removed from the test set, opened, and filled up to about three quarters with tap water.
BEHOLDERETIKET 200 mg/50 mg tabletter – beholderetiket
200 mg/50 mg tablets – Bottle label
Beholderne til udåndingsprøven (rør eller udåndingsposer) sendes til analyse til et kvalificeret laboratorium.
The breath sample containers (tube or breath bags) have to be sent for analysis, to a qualified laboratory.
Beholderpakning:
Bottle pack
Beholderpakning:
Bottle pack:
behov for at justere
therapy may need to be adjusted in some
behov for at lade en større urinmængde end normalt, behov for natlig vandladning, eller besværet eller manglende evne til at lade vandet, nedsat urinmængde
need to pass more urine than normal, need to pass urine during the night, difficulty or inability to pass urine or having an urine flow decreased
behov for at mildne
ymptoms.
Behov for behandling med inotrope midler
Requiring inotropes
behov for co-administration bør den
co-administration is required the
Behov for dosisreduktion af vitamin K-antagonister efter initiering af sitaxentanbehandling.
Need to decrease established dose of vitamin K antagonist upon starting sitaxentan therapy
Behov for kirurgisk indgreb
Requiring surgical intervention
Behov for monitorering af blodet
Need for blood monitoring:
Behov for måling af leverfunktionen:
Need for liver function tests to be measured:
Behov for præmedicinering
Need for premedication
Behov for re-implantationer skal baseres på forøget testikelstørrelse og/eller plasmatestosteronniveau samt genoptaget seksuel aktivitet.
Subsequent implantations should be based on the increase in testis size and/or increase in plasma testosterone concentrations as well as return to sexual activity.
Behov for regelmæssig kontrol af INR.
Need for regular monitoring of INR
Behov for transfusion (≥4 enheder)
Requiring transfusion (≥ 4 units)
Behov for tæt monitorering af leverfunktion og dosisjustering, hvis niveauet stiger til over 3 x øvre normalgrænse (ULN).
Need for close monitoring of liver function and dosage adjustment if levels rise above 3 x upper limit normal (ULN):
Behov for tæt monitorering og dosisjustering, hvis niveauerne øges til over 3 gange den normale øvre grænse (ULN):
Need for close monitoring and dosage adjustment if levels rise above 3 x upper limit normal (ULN):
behov for vandladning om natten
need to wake and pass urine at night
Behov for ”rescue”-behandling, n (%) p-værdia
Requiring rescue therapy, n (%) p-value a
Behov ikke fastlagtd
Need not established d
Behovet for antiepileptisk behandling bør overvejes hos patienter, der planlægger at blive gravide.
The need for anti- epileptic treatment should be reviewed in patients planning to become pregnant.
Behovet for antiepileptisk behandling bør overvejes hos patienter, der planlægger at blive gravide.
The need for anti-epileptic treatment should be reviewed in patients planning to become pregnant.
Behovet for at bestemme neutrofiltallet før behandlingen påbegyndes, efter 1-2 måneder og derefter periodevist, mens patienten er i behandling med, da behandling med Rilonacept Regeneron ikke bør påbegyndes hos patienter med neutropeni;
The need to measure neutrophil counts prior to initiating treatment, after 1 to 2 months and periodically thereafter while receiving Rilonacept Regeneron as treatment with Rilonacept Regeneron should not be initiated in patients with neutropenia;
behovet for at forklare, og sikre at patienter/plejere har forstået:
The need to explain to and ensure understanding of by patients/carers:
Behovet for at føre dagbog for at dokumentere hver enkelt behandling modtaget i hjemmet og medbringe denne ved hver konsultation.
The need to keep a diary to document each treatment received at home and to bring it at each visit
Behovet for at genbehandle katte, som har en sandsynlighed for reinfestation, og intervallet mellem sådanne behandlinger skal baseres på den ansvarlige dyrlæges vurdering.
The need to re-treat cats which are likely to be re-infested, and the time interval between such treatments, should be based on an assessment by the responsible veterinarian.
Behovet for at instruere patienten om:
The need to advise patients about:
Behovet for at instruere patienter i den korrekte teknik til selvadministration, når patienten indvilliger i og er i stand til at gøre dette, og vejledning af sundhedspersonale i indberetning af administrationsfejl;
The need to instruct patients on proper techniques for self-administration when the patient is willing and capable to do so, and guidance for Health Care Professionals on how to report administration errors;
Behovet for at kontrollere, at patienten ved, hvordan denne anvender bronkodilatoren korrekt.
The need to check that the patient knows how to correctly use the bronchodilator.
Behovet for at monitorere behandlingen, og hvornår behandling skal seponeres.
The need for monitoring and when to withhold treatment.
Behovet for at overvåge ændringer i patienternes lipidprofiler;
The need to monitor patients for changes in their lipid profiles;
Behovet for at rådgive patienter om vigtige risici forbundet med behandling med Vyndaqel, og passende forholdsregler ved brug af medicinen, især det at undgå at blive gravid og behovet for brug af sikker prævention.
The need to counsel patients on important risks associated with Vyndaqel therapy and appropriate precautions when using the medicine, particularly the avoidance of pregnancy and the need for effective contraception.
Behovet for at rådgive patienterne om vigtige risici i forbindelse med Eurartesim-behandlingen og hensigtsmæssige forholdsregler, når denne medicin anvendes.
The need to counsel patients on important risks associated with Eurartesim therapy and appropriate precautions when using the medicine.
Behovet for at stoppe behandlingen med FABLYN og foretage undersøgelser, hvis der opstår uforudset uterusblødning.
The need to stop treatment with FABLYN and investigate when unexplained uterine bleeding occurs.
Behovet for at søge akut behandling i tilfælde af, at der ikke kan opnås adgang til en vene eller i tilfælde af manglende effekt.
The need to seek urgent treatment in the event of failure to gain venous access or if there is a lack of efficacy
Behovet for at tage 15 mg- og 20 mg-tabletterne sammen med mad
The need for intake of the 15 mg and 20 mg tablets with food
Behovet for at tage EKG og kontrollere serumværdier af kalium, calcium og magnesium samt thyroid-stimulerende hormon (TSH), og de tider og situationer, hvor det bør udføres
The need for an ECG, and serum levels of potassium, calcium and magnesium and thyroid stimulating hormone (TSH) and the times and situations when it should be performed
Behovet for at udføre vurdering af initialdosen af Bronchitol for at identificere patienter, som har bronkial hyperreaktivitet over for inhaleret mannitol, ved at måle graden af bronkokonstriktion, som forekommer efter sekventiel administration af mannitol.
The need to perform the Bronchitol initiation dose assessment to identify patients who have bronchial hyperresponsiveness in response to inhaled mannitol by measuring the degree of bronchoconstriction that occurs following sequential administrations of mannitol.
Behovet for at undervise patienten i at minimere hoste under administration ved at benytte korrekt inhalationsteknik.
The need to train the patient to minimise cough during administration in using the correct inhalation technique.
Behovet for at vurdere risikoen for TB hos patienter før behandling med Inflectra.
The need to assess the risk of TB in patients prior to treating with Inflectra.
Behovet for at vurdere risikoen for TB hos patienter før behandling med Remicade.
The need to assess the risk of TB in patients prior to treating with Remicade.
Behovet for at vurdere risikoen for TB hos patienter før behandling med Remsima.
The need to assess the risk of TB in patients prior to treating with Remsima.
Behovet for at vurdere risikoen for TB hos patienterne før behandling med Flixabi.
The need to assess the risk of TB in patients prior to treating with Flixabi.
Behovet for at øge dosis ( %)
Need to increase the dose (%)
Behovet for behandling med antiepileptika bør revurderes, hvis en kvinde planlægger at blive gravid.
The need for anti-epileptic therapy should be reviewed when a woman is planning to become pregnant.
Behovet for en booster-dosis med hepatitis B-vaccine hos raske individer, som har modtaget et fuldt primært vaccinationsprogram, er ikke blevet fastlagt; dog indeholder nogle officielle vaccinations- programmer for tiden en rekommandation af en booster-dosis af hepatitis B-vaccine, hvilket skal respekteres.
The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.
Behovet for en booster-dosis med hepatitis B-vaccine hos raske individer, som har modtaget et fuldt primært vaccinationsprogram, er ikke blevet fastlagt; dog indeholder nogle officielle vaccinations- programmer for tiden en rekommendation af en booster-dosis af hepatitis B-vaccine, hvilket skal respekteres.
The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.
Behovet for en boosterdosis hos raske personer som har modtaget hele det primærvaccinations- program er ikke fastlagt.
The need for a booster dose in healthy individuals who have received a full primary vaccination course has not been established.
Behovet for en boosterdosis hos raske personer som har modtaget hele det primærvaccinationsprogram er ikke fastlagt.
The need for a booster dose in healthy individuals who have received a full primary vaccination course has not been established.
Behovet for en boosterdosis med hepatitis B-vaccine hos raske personer, som har modtaget et fuldt primært vaccinationsprogram, er ikke blevet fastlagt; dog indeholder flere officielle vaccinations- programmer for tiden en rekommendation af en boosterdosis af hepatitis B-vaccine, hvilket skal respekteres.
The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.
Behovet for fortsat behandling bør genovervejes hver 6. måned.
The need for treatment continuation should be reconsidered every 6 months.
Behovet for fortsat behandling bør som minimum overvejes en gang årligt på baggrund af lægens vurdering af sygdommens sværhedsgrad, og på hvilket niveau patientens eksacerbationer kontrolleres.
The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient’s disease severity and level of control of exacerbations.
Behovet for fortsat observation af patienter med risikofaktorer for toksinspredning fra injektionsstedet til andre dele af kroppen og identifikation af disse patienter, så der kan udvises forsigtighed.
The need for continued observation for patients with risk factors for toxin spread from the site of injection to other parts of the body and identification of these patients so caution can be exercised.
Behovet for graviditetstest inden behandlingen og månedligt under behandlingen og for monitorering af hæmoglobinniveauer og leverfunktion.
The need for baseline and monthly pregnancy tests and monitoring of haemoglobin levels and liver function.
behovet for i henhold til normal klinisk praksis at undersøge fortykkelse af endometriet efter seponering af behandlingen og menstruationens tilbagevenden for at udelukke andre underliggende sygdomme. anbefaling af periodisk overvågning af endometriet ved gentaget intermitterende behandling.
the need to investigate as per usual clinical practice persistence of endometrial thickening following treatment discontinuation and return of menstruation to exclude other underlying conditions. recommendation of a periodic monitoring of the endometrium in case of repeated intermittent treatment.
Behovet for lokal- eller spinalanæstesi
The need for regional or spinal anaesthesia
Behovet for månedlige graviditetstest;
The need for monthly pregnancy tests;
Behovet for og valget af præmedikation er op til dyrlægens vurdering.
The necessity for and choice of premedication is left to the discretion of the veterinarian.
Behovet for professionel overvågning og monitorering, hvis der træffes en klinisk beslutning om at skifte en patient til et andet tacrolimus-indeholdende produkt.
The need for specialist supervision and monitoring if there is a clinical decision to switch a patient to another tacrolimus containing products.
Behovet for præmedicinering med en bronkodilator 5-15 minutter før vurderingen af den initiale Bronchitol-dosis og før terapeutisk administration af Bronchitol.
The need of pre-medication by a bronchodilator 5-15 minutes before the Bronchitol initiation dose assessment and before each therapeutic administration of Bronchitol.
Behovet for regelmæssig monitorering af leverfunktionen, fordi Opsumit har hepatotoksisk potentiale.
The need for regular monitoring of liver function because Opsumit has hepatotoxic potential.
Behovet for regelmæssige blodprøver, fordi Opsumit forårsager et fald i hæmoglobin;
The need for regular blood tests because Opsumit causes a decrease in haemoglobin;
Behovet for rådgivning af patienter om risici relateret til administrationen af XALKORI og informere om symptomer og hvilke forholdsregler patienten skal tage.
The need to counsel patients about risks related to the administration of XALKORI and inform them of what symptoms and signs to be aware of and the actions to take.
Behovet for screening af donorer ved hjælp af patientspørgeskema og laboratorieprøver for hepatitis C, hepatitis B, HIV og syfilis
The need for screening of donors using patient questionnaire and laboratory tests for hepatitis C, hepatitis B, HIV, and syphilis
Behovet for smertebehandling
The need for pain management
Behovet for sårrensning og forberedelse før behandling med
The need for wound cleansing and preparation before treatment with
Behovet for tilstrækkeligt indtag af calcium- og Vitamin D-tilskud, passende fysisk aktivitet, rygestop og sund diæt
Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non- smoking and healthy diet
Behovet for tilstrækkeligt indtag af calcium- og Vitamin D-tilskud, passende fysisk aktivitet, rygestop og sund diæt
Need for adequate calcium and vitamin D supplementation, appropriate physical activity, non-smoking and healthy diet
behovet om at bære patientsikkerhedskortet og fortælle eventuelt sundhedspersonale at han/hun modtager behandling med eculizumab
the need to carry the patient safety card and to tell any healthcare practitioner that he/she is receiving treatment with eculizumab
Behovsbehandlingen med NovoThirteen af akutte blødninger eller gennembrudsblødninger er ikke blevet undersøgt i kliniske studier.
The on-demand treatment of acute bleeds or breakthrough bleeds with NovoThirteen has not been studied in clinical trials.
Beige granulært pulver.
A beige granular powder.
Beige tabletter med form som en aflang sekskant, præget med ”10 MG” på den ene side og ”4759” på den anden.
Beige and double-arrow shaped tablets, debossed with “10 MG” on one side and “4759” on the other.
Beige, ovale filmovertrukne tabletter på 14,0 mm x 8,0 mm præget med "AV2" på den ene side.
Beige, ovaloid, film-coated tablets with dimensions of 14.0 mm x 8.0 mm and debossed on one side with ‘AV2’.
Beigefarvede, trekantformede overtrukne tabletter mærket “RAPAMUNE 0.5 mg” på den ene side.
Tan-coloured, triangular-shaped coated tablet marked “RAPAMUNE 0.5 mg” on one side.
Bekræft
Confirm
Bekræft aflevering af dosis
Confirm dose delivery
Bekræft at du får en fuldstændig injektion (7) eller registrer det viste nummer på skærmen med dosisfeedback, hvis det ikke er ”0” (8).
Confirm you receive a complete injection (7) or record the number shown in the Dose Feedback Window if other than ‘’0’’ (8).
Bekræft forhøjelsen ved gentagelse af bestemmelsen inden for en uge.
Confirm elevation with a repeat measurement within one week.
Bekræft hvilken streng, der skal injiceres i.
Reconfirm the cord to be injected.
Bekræfte, at din behandling har virket, og at du er fri for hepatitis C-virus.
Confirm that your treatment has worked and you are free of the hepatitis C virus.
bekræftelse af første negativ graviditetstest inden påbegyndelse af behandling (hvis kvinde i den fertile alder) datoerne for graviditetstest og resultat
verification of initial negative pregnancy test prior to start of treatment (if female with childbearing potential) pregnancy test dates and results
Bekræftelse af patientens forståelse af risikoen forbundet med thalidomid og forholdsreglerne i svangerskabsforebyggelsesprogrammet
Affirmation of patient understanding regarding the risk of thalidomide and the PPP measures
Bekræftelse af, at lægen har drøftet risikoen for at udvikle PML og IRIS, hvis behandlingen afbrydes på grund af mistanke om PML
Confirmation that the doctor has discussed the risks of PML and the risk of IRIS if treatment is discontinued following suspicion of PML
Bekræftelse af, at lægen har talt med patienten om:
Confirmation that the physician has discussed the following:
Bekræftelse af, at patienten forstår risikoen for at udvikle PML, og at patienten har modtaget en kopi af formularen samt et patientinformationskort
Confirmation of patient understanding of the risks of PML and that they have received a copy of the form and a patient alert card
bekræftelse af, at relevant rådgivning har fundet sted
verification that appropriate counselling has taken place
Bekræftelse på at der er gennemført en passende rådgivning
Verification that appropriate counselling has taken place
Bekræftelse på, at patienten har fået relevant rådgivning
Verification that appropriate counselling has taken place
Bekræftelse vedrørende egnede omgivelser (tilgængeligt genoplivningsudstyr) forud for administration af ferumoxytol
Confirmation on appropriate settings (emergency resuscitation equipment available ) prior to administration of ferumoxytol
bekræftende forsøg for at undersøge virkningen og sikkerheden af ataluren 10, 10,
confirmatory study to examine efficacy and safety of ataluren 10, 10, 20 mg/kg in
Bekræftende kliniske studier hos voksne behandlingsnaive patienter
Confirmatory clinical trials in adult treatment-naïve patients
Bekræftet ALAT eller ASAT > 3 x ULN og bilirubin > 2 x ULN
Confirmed ALT or AST > 3 x ULN and bilirubin > 2 x ULN
Bekræftet forhøjelse af serumkreatinin
Confirmed increase in serum creatinine